Revenues (Tables)

6 Months Ended

Jun. 30, 2018

Revenue from Contract with Customer [Abstract]

The following table presents a summary of total revenues (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Xyrem	$	356,008	$	298,026	$	672,785	$	570,352
Erwinaze/Erwinase	58,713		49,024		109,340		100,412
Defitelio/defibrotide	40,498		30,238		75,559		66,138
Vyxeos	27,951		—		54,179		—
Prialt	8,921		5,656		15,047		13,373
Other	4,004		6,711		10,032		13,058
Product sales, net	496,095		389,655		936,942		763,333
Royalties and contract revenues	4,384		4,731		8,150		7,106
Total revenues	$	500,479	$	394,386	$	945,092	$	770,439

The following table presents a summary of total revenues attributed to geographic sources (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
United States	$	455,359	$	356,687	$	861,046	$	695,870
Europe	35,018		27,378		63,349		58,730
All other	10,102		10,321		20,697		15,839
Total revenues	$	500,479	$	394,386	$	945,092	$	770,439

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Express Scripts	71	%	75	%	71	%	74	%
McKesson	20	%	14	%	20	%	15	%

Summary of a reconciliation in contract liabilities from contracts with customer

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the six months ended June 30, 2018 (in thousands):



	Contract Liabilities
Balance as of December 31, 2017	$	24,733
Effect of adoption of ASU 2014-09	(2,240		)
Amount recognized within royalties and contract revenues	(3,749		)
Balance as of June 30, 2018	$	18,744